Search CDDW 2007 Abstracts

HOME

Return to Table of Contents

157

REQUEST^TM IS A POWERFUL INSTRUMENT TO DIFFERENTIATE TREATMENT RESPONSE

¹ABR Thomson, ²S Peter
¹Division of Gastroenterology, University of Alberta, Edmonton, Alberta; ²Clinical Research Gastroenterology, ALTANA Pharma AG, Konstanz, Germany

PURPOSE: ReQuest^TM is a validated questionnaire to evaluate GERD symptoms and related impacts on quality of life. To determine whether this questionnaire is suitable to detect differences in the response to treatment with different proton pump inhibitors the ReQuest^TM database was reviewed.
METHODS: The ReQuest^TM database contains data from 14 clinical trials with symptom assessment based on the reflux questionnaire ReQuest^TM. The following inclusion criteria applied to patients in all trials: at least 18 years of age and diagnosis of GERD, erosive GERD confirmed by endoscopy with or without symptoms or enGERD (endoscopy negative GERD) confirmed by endoscopy and symptom-based diagnosis (history of frequent GERD-related symptoms during the last 3 months and acid complaints for at least 3 days during the last week prior to study start). The database was used to compare the mean acid dimension score and the ReQuest^TM-GI sum score at baseline and day 28 for patients treated with pantoprazole 40mg and esomeprazole 40mg.
The Wilcoxon rank sum test was used throughout this procedure.
RESULTS: Within the tested population (N=3967) the mean scores for the acid dimension and the ReQuest^TM-GI for patients treated with pantoprazole 40mg and esomeprazole 40mg were lower on day 28 than on baseline. In the acid dimension scores the mean pre-post differences were -2.32 (±2.01) for pantoprazole 40mg and -2.12 (±2.12) for esomeprazole 40mg (ie, 9%). The differences between the scores of ReQuest^TM-GI were -5.33 (±5.38) for pantoprazole 40mg and -4.44 (±4.97) for esomeprazole 40mg (ie, 17%). For both scores the mean pre-post difference for patients treated with pantoprazole 40mg significantly exceeded the values for esomeprazole 40mg (p<0.0001).
CONCLUSIONS: The ReQuest^TM-GI sum score is a powerful and sensitive instrument to evaluate differences in treatment responses. Treatment of GERD with pantoprazole 40mg resulted in a significantly higher response than with esomeprazole 40mg.
Study funded by ALTANA Pharma AG

PREVIOUS     NEXT